Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
Francisco Chacón-Lozsán/LinkedIn
May 27, 2026, 04:29

Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI

Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared a post on LinkedIn about a recent article by Rupak Desaia et al, published in Current Medical Research and Opinion, adding:

“NSTEMI management is no longer ‘troponin positive chest pain.’

It is a risk stratified emergency pathway.

Recent PubMed indexed guidelines converge on a practical message: high sensitivity cardiac troponin is the biomarker of choice, but NSTEMI diagnosis still requires clinical context, ECG, serial change, and exclusion of alternative causes of myocardial injury. (Byrne et al., 2023; Rao et al., 2025)

Troponin T and troponin I are both valid for diagnosis, but they are not interchangeable.

Each assay has its own thresholds, kinetics, analytical behavior, and confounders.

Troponin T may be more frequently elevated in chronic kidney disease, skeletal muscle disease, and advanced age, while troponin I is often considered more cardiac specific at the molecular level. (Byrne et al., 2023; Desai et al., 2024)

CK, CK MB, LDH, and myoglobin should not drive modern NSTEMI diagnosis when high sensitivity troponin is available.

Their incremental diagnostic value is limited, although CK MB may still have niche roles where troponin is unavailable or in selected reinfarction scenarios. (Byrne et al., 2023)

TTE is not optional in unstable ACS.

It helps identify regional wall motion abnormalities, LV and RV dysfunction, acute mitral regurgitation, ventricular septal rupture, tamponade, pulmonary embolism mimics, aortic pathology, and shock phenotype.

However, echocardiography must never delay catheterization when acute coronary occlusion is suspected. (Byrne et al., 2023)

When is PCI mandatory?

In NSTEMI with shock, refractory ischemia, malignant arrhythmias, acute heart failure, mechanical complications, or hemodynamic instability, the question is not ‘observe or cath.’

It is emergency angiography with PCI if feasible.

In cardiogenic shock, immediate coronary angiography and culprit lesion PCI are recommended, while routine multivessel PCI during the index procedure should generally be avoided. (Byrne et al., 2023; Rao et al., 2025)

For stable NSTEMI, PCI timing depends on risk.

High risk patients, including ruled in NSTEMI, dynamic ST or T wave changes, transient ST elevation, or GRACE score above 140, should generally undergo early invasive angiography within 24 hours. (Byrne et al., 2023)

The modern NSTEMI question is not simply:

‘Is troponin positive?’

It is:

‘Is this type 1 MI, how unstable is the patient, what is the myocardium doing, and how fast must we open the artery?’

References

Title: A systematic review and meta-analysis evaluating the association of high sensitivity troponin levels with outcomes in patients with stable coronary artery disease

Authors: Rupak Desai, Nanush Damarlapally, Srijan Bareja, Vaishnavi Arote, Srivatsa SuryaVasudevan, Kamya Mehta, Mariam Ashfaque, Yadeshini Jayachandran, Shrikanth Sampath, Alaknanda Behera, Archit Srivatsava, Shariq Nawab, Sriharsha Dadana

Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI

Stay updated on all scientific advances with Hemostasis Today.

Alaknanda Behera Archit Srivatsava Current Medical Research and Opinion Francisco Chacón-Lozsán Health Hematology Hemostasis Hemostasis News Hemostasis Today High-Sensitivity Troponin Kamya Mehta Mariam Ashfaque Medicine Nanush Damarlapally NSTEMI PubMED Rupak Desai Shariq Nawab Shrikanth Sampath Sriharsha Dadana Srijan Bareja Srivatsa SuryaVasudevan ST elevation Vaishnavi Arote Yadeshini Jayachandran
NewsFeed